Audit: QRS - Caffeic Acid Phenethyl Ester for Health & Longevity

Audit conducted on 10/09/2026 03:02 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	93
Passed	87
Failed	0
N/A	6
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Spot-checked every populated span: dosing 226–1500 mg (ER 405), 900 mg clustering (ER 405), split dosing (ER 415), timing (ER 417), 8–24 / 8–12 week windows (ER 460, 490), 3-day URI remission (ER 193), all 10 markers and targets (ER 494–503), all gate items (ER 345–379).
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	“No protocol exists for the isolated compound” (line 457) and “half-life is unmeasured in humans” (line 471) mirror ER 403 and 413; “local, short-term effect only” mirrors ER 191.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Tier placement matches the ER exactly (no High/Medium benefits, Medium risk = contact dermatitis); “Pregnancy and lactation” stays in the stop gate, not the caution gate.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Stop items come from the ER “Populations who should avoid” list (ER 369–379); caution items from the ER interaction bullets (ER 345–367). No modifying factors appear in either gate.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	No PMIDs, author names, NCT numbers or brand names (EPP-AF, Comvita, Apis Flora) appear anywhere in the QRS.
1.6	The QRS does not introduce new attributions.	🟢	No attributions of any kind in the sheet.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Sober, evidence-graded register throughout, matching the ER’s repeated distinction between isolate and whole-extract data.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Quantified targets and windows are given without hedging or alarm; the sheet states what can be tracked and when.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Descriptive constructions (“Common practice given…”, “trials detecting glycemic and lipid change ran…”) rather than instructions.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	No imperatives; the footer disclaimer is the template’s own.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	No occurrences of “recommend”, “advise”, “should take” or equivalents; “Nothing meaningful should be expected before two months” is ER wording (ER 460).
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person pronouns anywhere in the document.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Technical terms are glossed or plain (“the enzyme that makes urate”, “averages blood sugar over roughly three months”); the At-A-Glance lede is fully jargon-free.
2.8	Information is presented in a concise and very compact manner	🟢	Gate items are single clauses, benefit and risk tiers are semicolon-separated noun phrases, marker rows are three short cells.
2.9	It DOES NOT address the reader directly	🟢	Confirmed: no “you”/”your” in any span.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Optimal-range targets (hs-CRP below 0.5 mg/L, HbA1c 4.9–5.4%) rather than conventional disease cutoffs.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Ten-marker panel, split dosing with meals and weekly skin checks are all presented as ordinary expectations.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	No simplified “ask your doctor” framing; assumes access to IL-6, eosinophil count and home blood-pressure averaging.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	The lede foregrounds the absence of isolate data and the sourcing problem — the two facts that decide use for this audience.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	“anti-aging” does not occur; the title uses “for Health & Longevity”.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt.	🟢	Route and event terms are formal (“oral spray”, “gastrointestinal intolerance”, “allergic contact dermatitis”, “systemic hypersensitivity”); “blood sugar” appears only inside an ER-verbatim explanation of glycated hemoglobin.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: • Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment” • Gate headings: “Contraindications”, “Key Interactions” • Tier labels: “High”, “Medium”, “Low”, “Speculative” • Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All headings, gate headings, tier labels and column headers match the template byte-for-byte.
3.2	All “<span data-qrs-var=”NAME”>…</span>” from the [qrs_template] are present in the the QRS.	🟢	Diff of the span-name sets against the template shows only the expected expansions of marker_#* (1–10) and qualitative_item# (1–6); 70 spans present.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	Head, style block, website=”evidence_review”/”audit”/”full_review” spans and footer are identical to the template.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No section of the source ER is empty; the empty High/Medium benefit and High risk tiers are governed by 12.5 and 13.5.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	Protocol labels “Standard extract dosing”, “Split rather than single dosing”, “Best time of day” are the ER’s bold labels (ER 405, 415, 417); caution items reuse the ER interaction labels verbatim.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Marker names match the ER biomarker table exactly; benefit and risk items reuse the ER subsection headings.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	Zero emoji characters in the file; tiers are rendered with CSS classes and bold labels only.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Every section is heavily condensed against the ER (13 protocol bullets → 3 cells, 8 benefit subsections → 1 line, 10-row biomarker table stripped to three columns); no section carries ER prose across.

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Lines 2–14: the metadata comment immediately follows the doctype and precedes every other element.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening “—” at line 3, closing “—” at line 13.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Enclosed in an HTML comment; no metadata value is repeated in the header or body.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only duration: “00:04” is quoted, correctly, because it contains a colon.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	Line 4: er_filename: caffeic_acid_phenethyl_ester_2026-0910-0002_Opus_ER.md.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	Line 5: qrs_prompt_version: 26.7.02, matching the QRS.md version badge.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	Line 6: qrs_creation_date: 2026-0910-0248.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	Line 7: qrs_creator_ai_nickname: Opus.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	“Opus” — single word, no version.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	Line 8: qrs_creator_ai_fullname: Opus 5.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” — nickname plus version, no qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	Line 9 matches the actual filename caffeic_acid_phenethyl_ester_2026-0910-0002_Opus_QRS.html.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	All ten keys are single-space separated with no trailing whitespace; git_issue: 5977 and git_user: evipedia-4 are unquoted as required.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	Line 22: “Caffeic Acid Phenethyl Ester for Health & Longevity - Quick Reference Sheet”.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	Line 417 matches the ER canonical_topic with the ampersand encoded.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	Line 421: 09/10/2026, from qrs_creation_date 2026-0910-0248.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	Line 425: Opus 5.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	The header holds only the title and the template subline; no alternate-names line despite the ER carrying five.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Condenses ER 536–542: mechanism, absence of isolate trials, extract-only human data, allergy harm, origin-dependent content.
7.2	[at_a_glance] is no longer than 60 words	🟢	52 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Four claims map to ER 536, 538, 542 and 542 respectively.
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	No acronyms; “propolis”, “NF-κB” and “polyphenol” are rendered as “bee resin”, “a central inflammatory control system” and are avoided entirely.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No study, author, year or sample size appears.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No numbers of any kind in the lede.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All ten items trace to the ER “Populations who should avoid” list (ER 369–379) within that section.
8.2	[stop_items] represent the Contraindications from the ER	🟢	Complete: all nine ER bullets are represented, with the final combined bullet split into “Anyone under 18” and “Active cancer treatment without oncologist sign-off”.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Ten <li> elements inside the stop_items span (lines 572–589).
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	ER rationale clauses are stripped throughout (“given documented cross-reactivity”, “where no human safety data of any kind exist”, “given wholly uncharacterized human clearance”, “where contaminant clearance is impaired”).
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Retained: INR 2.0–3.0 and the three-month instability window, the 14-day pre-procedure window, Child-Pugh Class B or C, CKD stage 4 or 5 with (below 30 mL/min/1.73 m²), age 18.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	🟢	The ER uses no ranking notation here; the only parenthetical retained is a numeric threshold, carried without bare symbols.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	The ER names nine such populations, and the section is correctly populated rather than empty.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. <!– empty: ER names no population that should avoid the intervention –>	N/A	The section is not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All eleven items are the ER interaction bullets at ER 345–365.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	Eleven of the ER’s twelve interaction bullets are carried; “Cytotoxic chemotherapy and radiotherapy” is correctly omitted because it is an absolute contraindication already in the stop gate.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Eleven <li> elements inside the caution_items span (lines 597–622).
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Each item is the drug-class label plus its example list; every ER rationale sentence (“caution”, “monitor”, mechanism, INR-recheck advice) is stripped.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	All eleven parenthetical drug lists are preserved verbatim from the ER bullets.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	🟢	The ER parentheses are plain comma-separated drug lists; no ranking symbols appear.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	The ER lists twelve interactions, and the section is correctly populated.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. <!– empty: ER names no interaction that changes how the intervention is used –>	N/A	The section is not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	All three cells trace to the ER Therapeutic Protocol bullets at ER 403, 405, 413, 415 and 417.
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Dose, dosing frequency and timing are the only three executable aspects in that section; the remaining bullets are competing approaches, pharmacology and modifying factors.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies three distinct actionable aspects, so no set is unused.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	All nine spans populated; the ER caveat that no isolate protocol exists is carried into action_1_sub.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Inflammation, glycemic/lipid and upper respiratory symptoms are the only endpoints for which the ER gives a time course (ER 193, 460, 490).
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Inflammation first (largest pooled effect, SMD −1.73, ER 169), then the cardiometabolic markers, then the local upper respiratory effect.
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	Three distinct aspects exist in the ER, so no set is unused.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	All nine spans populated; values 8–12 weeks, 8–24 weeks and 3 days all appear in the ER.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER provides time-to-effect information, so the section is correctly retained.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	All items are ER Expected Benefits subsection headings (ER 165–249).
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans present at lines 544–562.
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Semicolon-separated noun phrases only; no magnitudes, confidence intervals or “⚠️ Conflicted” markers carried over.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear in either benefit tier.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective <SPAN> is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	The ER has no High or Medium benefits; both spans are emptied and set to style=”display: none” (lines 544–545).

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	All items are ER Potential Risks & Side Effects subsection headings (ER 277–325).
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans present at lines 634–651.
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Patch-test percentages, case-report detail and mechanism sentences from the ER are all omitted.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear in any risk tier.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective <SPAN> is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	The ER has no High risk; the span is emptied and set to style=”display: none” (line 634).

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	Rows reproduce the ER Monitoring Protocol & Defining Success biomarker table (ER 492–503).
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All ten ER biomarkers present, with targets carried verbatim, including the eosinophil and uric-acid safety markers.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Line 811 condenses ER 490, including the weekly warfarin clotting check for the first month.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	Items are the ER’s “Qualitative markers worth tracking alongside the labs” list (ER 505–512).
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All six ER qualitative markers are present, verbatim.

Issues 10/09/2026 03:02

Pass rate 100.00%. No issues found.

Issues 10/09/2026 02:55

1. 1.3 — Cancer-treatment contraindication narrowed: Contraindication item 10 (QRS line 587) reads “Cytotoxic chemotherapy or radiotherapy without oncologist sign-off”, narrowing the ER’s broader avoid-population “anyone receiving active cancer treatment without oncologist sign-off” (ER line 379).
2. 2.15 — Colloquial “dental work”: Contraindication item 5 (QRS line 582) uses the consumer-grade “dental work” in place of the ER’s own “elective surgical or dental procedure involving bleeding risk” (ER line 375).

Fixes 10/09/2026 02:55

1. 1.3 — Cancer-treatment contraindication restored: Changed the tenth contraindication from “Cytotoxic chemotherapy or radiotherapy without oncologist sign-off” to “Active cancer treatment without oncologist sign-off”, restoring the ER’s full avoid-population.
2. 2.15 — Colloquial “dental work” replaced: Changed the fifth contraindication from “Within 14 days of elective surgery or dental work with bleeding risk” to “Within 14 days of elective surgical or dental procedures with bleeding risk”.